Flash Finance

TTK Healthcare LimitedTTKHLTCARECorporate

Diversified - Medium / Small Latest results: Mar 2026 13 quarters of data
₹1,035.00
MCap ₹1,462 Cr · P/E 22.2
TTK Healthcare Limited — Stock analysis & AI research TTK Healthcare Limited — Multibagger AI analysis TTK Healthcare Limited — Seasonality — best & worst months TTK Healthcare Limited — Technical setup — score, trend, support & resistance TTK Healthcare Limited — Live exchange announcements
📋 High Promoter Holding Stocks 📈 MACD Bullish Crossover📈 Bollinger Squeeze Stocks
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹218 Cr
Sales · Mar 2026
+14.7% YoY
₹11 Cr
Operating Profit · Mar 2026
-8.3% YoY
5.0%
OPM % · Mar 2026
-20.6% YoY
₹22 Cr
Net Profit · Mar 2026
+37.5% YoY
₹15.40
EPS · Mar 2026
+34.7% YoY

📝 TTK Healthcare Limited — results explained

Quarter ended March 2026 (Q4 FY26)

TTK Healthcare Limited reported revenue of ₹218 crore for the quarter ended March 2026 (Q4 FY26), up 14.7% from ₹190 crore in the same quarter last year, and up 4.3% sequentially over the December 2025 quarter.

Net profit rose 37.5% year-on-year to ₹22 crore, from ₹16 crore. Earnings per share (EPS) came in at ₹15.40.

Operating profit stood at ₹11 crore — an operating margin (OPM) of 5.0%, compared with 6.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, TTK Healthcare Limited posted revenue of ₹857 crore, a growth of 7.0% over FY25, with a net profit of ₹66 crore (down 19.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹857 crore with a net profit of ₹66 crore.

Valuation snapshot

At the current price of ₹1,035.00, TTKHLTCARE has a market capitalisation of ₹1,462 crore and a trailing P/E of about 22.2.

Within the Diversified - Medium / Small industry, it is the largest of the 8 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 74.56%, foreign institutional investors (FIIs) 1.95%, domestic institutional investors (DIIs) 0.12%, public shareholders 23.38% of TTK Healthcare Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,462 Cr
Current Price ?
₹1,035.0
P/E ?
22.16above ind
Industry P/E ?
13.10
P/B ?
1.31
P/S ?
1.71
P/FCF ?
-58.50
Enterprise Value ?
₹1,486 Cr
EV/EBITDA ?
57.17
PEG ?
N/A
Earnings Yield ?
1.2%
Dividend Yield ?
0.97%
Profitability & Returns
Sales (TTM) ?
₹857 Cr
OPM ?
3.0%
Profit after tax (TTM) ?
₹66 Cr
EPS (TTM) ?
₹46.71
ROCE ?
8.0%
ROE ?
5.9%
ROA ?
5.0%
Growth
Sales — latest qtr ?
₹218 Cr
PAT — latest qtr ?
₹22 Cr
YoY qtr sales growth ?
14.7%
YoY qtr profit growth ?
37.5%
Sales growth (3y) ?
6%
Sales growth (5y) ?
12%
Profit growth (3y) ?
-52%
Profit growth (5y) ?
11%
Financial Health
Debt ?
₹24 Cr
Debt to Equity ?
0.02
Interest Coverage ?
4.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
74.56%
Change in promoter holding ?
-0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
5.6%
Return 6 months ?
18.6%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 180202186184181208198205190226204209218 +14.7% +4.3%
Operating Profit 1510105127881235711 -8.3% +57.1%
Other Income 12151616163718181318191021 +61.5% +110.0%
Interest 1110111111111 +0.0% +0.0%
Depreciation 3333322222222 +0.0% +0.0%
Profit Before Tax 23212218244123232218211430 +36.4% +114.3%
Net Profit 17161613183217171613201122 +37.5% +100.0%
EPS 11.9911.0911.339.1212.9322.3512.1711.8411.439.2014.437.4515.40 +34.7% +106.7%
OPM % 8.3% 5.0% 5.4% 2.7% 6.6% 3.4% 4.0% 3.9% 6.3% 1.3% 2.5% 3.3% 5.0% -20.6% +51.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹801 Cr ₹857 Cr ₹857 Cr +7.0%
Operating Profit ₹35 Cr ₹26 Cr ₹26 Cr -25.7%
OPM % 4.37% 3.03% 3.03% -30.7%
NPM % 10.24% 7.70% 7.70% -24.8%
Other Income ₹86 Cr ₹68 Cr ₹68 Cr -20.9%
Depreciation ₹8 Cr ₹8 Cr ₹8 Cr +0.0%
Interest ₹4 Cr ₹4 Cr ₹4 Cr +0.0%
EBIT ₹27 Cr ₹18 Cr ₹18 Cr -33.3%
PBT ₹109 Cr ₹83 Cr ₹83 Cr -23.9%
Tax — — — —
Net Profit ₹82 Cr ₹66 Cr ₹66 Cr -19.5%
EPS ₹57.79 ₹46.48 ₹46.48 -19.6%
Material Cost — — — —
Employee Cost — — — —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 14141414 +0.0%
Reserves 9399871,0511,101 +4.8%
Borrowings 27232424 +0.0%
Other Liabilities 189183192190 -1.0%
Total Liabilities 1,1701,2061,2811,329 +3.7%
Fixed Assets 71758173 -9.9%
CWIP 3101 —
Investments 1313119 -18.2%
Other Assets 1,0831,1181,1891,246 +4.8%
Total Assets 1,1701,2061,2811,329 +3.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -25-5-4-21 -425.0%
Cash from Investing Activity 32282052 +160.0%
Cash from Financing Activity -12-22-18-18 +0.0%
Net Cash Flow -62-213 +750.0%
Free Cash Flow -36-156-25 -516.7%
CFO/OP -28%54%68%-3% -104.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 46424147 +14.6%
Inventory Days 8910510798 -8.4%
Days Payable 11611010683 -21.7%
Cash Conversion Cycle 19364363 +46.5%
Working Capital Days 44948161 +235.4%
ROCE % 10%9%9%8% -11.1%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 74.57%74.57%74.57%74.57%74.56%74.56% +0.0%
FIIs 1.89%1.90%1.89%1.90%1.86%1.95% +4.8%
DIIs 1.18%1.18%1.08%1.11%2.19%0.12% -94.5%
Public 22.37%22.37%22.46%22.43%21.39%23.38% +9.3%
No. of Shareholders 16,11216,13422,48123,68622,80923,993 +5.2%

⚖️ Peer comparison

Industry: Diversified - Medium / Small · 8 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 TTKHLTCARE TTK Healthcare ₹1,007.10 1,423 21.7 857 66 3.0% 7.7% 7.0% -19.5% 14.7% 37.5%
2 ANDREWYU Andrew Yule ₹26.11 1,277 0.7 5,854 1,974 -48.4% 33.7% 0.8% 839.4% -5.5% -5020.6%
3 BCLIND Bcl Industries ₹33.96 1,002 8.6 2,622 129 9.5% 4.9% 6.2% 29.8% -21.3% 7.6%
4 TARACHAND Tara Chand ₹45.67 360 15.7 291 23 34.7% 7.9% 20.7% 42.4% 10.7% -74.0%
5 SPECTSTM Spectrum Talent ₹109.80 254 20.7 1,450 12 1.0% 0.8% — — 0.4% 253.9%
6 GILLANDERS Gillanders Arbuthnot ₹103.00 220 12.6 434 17 6.9% 4.0% -2.8% -64.6% 3.3% 146.2%
7 VIKASECO Vikas EcoTech ₹1.05 146 75.8 369 3 1.6% 0.8% -6.5% -81.5% 15.1% -15.6%
8 INDIFRA Indifra ₹33.70 25 n/m 17 0 -1.8% 0.1% — — 582.5% 157.7%
❓ Frequently asked questions
What was TTK Healthcare Limited's revenue in Q4 FY26?
TTK Healthcare Limited reported revenue of ₹218 crore for the quarter ended March 2026 (Q4 FY26), up 14.7% from ₹190 crore in the same quarter last year, and up 4.3% sequentially over the December 2025 quarter.
What was TTK Healthcare Limited's net profit in Q4 FY26?
Net profit rose 37.5% year-on-year to ₹22 crore, from ₹16 crore. Earnings per share (EPS) came in at ₹15.40.
What is TTKHLTCARE's market capitalisation and P/E ratio?
At the current price of ₹1,035.00, TTKHLTCARE has a market capitalisation of ₹1,462 crore and a trailing P/E of about 22.2.
Who owns TTK Healthcare Limited? (shareholding pattern)
As of Sep 2026, promoters held 74.56%, foreign institutional investors (FIIs) 1.95%, domestic institutional investors (DIIs) 0.12%, public shareholders 23.38% of TTK Healthcare Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI